Company / Working Capital
Regeneron Pharmaceuticals Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$13.7B
FY2025
5-year range
$10.1B / $16.1B
FY2021-FY2025
Trend
-7.2%
vs FY2024
Sector context
#3 of 213
Health Care
What the data says
Among 213 Health Care companies, Regeneron Pharmaceuticals is in the top 1% for working capital. Declined from $16.1B to $13.7B over the past 2 years.
Based on SEC 10-K filings.
$13.7B in FY2025 with a 5-year CAGR of +14.0%. Ranks 3rd among 213 companies in Health Care.
Declined from $16.1B to $13.7B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +2.3%
- 5-Year CAGR
- +14.0%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 213This company $13.7B Sector average $934.6M
▼
+1360.9% above sector average
Key checks
Key Insights
- 5-year CAGR of +14.0%, indicating consistent growth.
- In FY2025, working capital decreased 7.2% year-over-year.
- Ranks #3 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.7B | -7.2% |
| FY2024 | $14.7B | -8.3% |
| FY2023 | $16.1B | +26.0% |
| FY2022 | $12.7B | +26.4% |
| FY2021 | $10.1B | +42.4% |
| FY2020 | $7.1B | +26.6% |
| FY2019 | $5.6B | +11.7% |
| FY2018 | $5.0B | +56.4% |
| FY2017 | $3.2B | +65.0% |
| FY2016 | $1.9B | -7.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026